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Background: The Heart Outcomes Prevention Study (HOPE) demonstrated that ramipril 
resulted in a blood-pressure-independent 25% reduction in cardiovascular events in patients 
with peripheral arterial disease (PAD). Despite this, general practitioners and vascular surgeons 
remain reluctant to prescribe ACE inhibitors in this group of patients because of concerns 
about renal artery stenosis (RAS). We aimed to deﬁ  ne the effect of ramipril on renal function 
in patients with intermittent claudication (IC).
Methods and Results: Of 132 unselected patients with IC entering the study 78 (59%) were 
excluded due to: current ACE inhibitor use (38%), renal impairment (serum creatinine above 
normal range) (15%), known severe RAS (1%) or unwillingness to participate (5%). The 
remaining 54 patients were titrated to 10 mg ramipril and renal function was monitored at 1, 5, 
and 12 weeks. Treatment was discontinued during titration in 5 patients due to symptoms (3) 
or lack of compliance (2). In the remainder, median [IQR] serum creatinine increased (94 
[85.8–103.3] to 98 [88.0–106.5] µmol/L, p  0.001) and median [IQR] GFR decreased (71.5 
[64.6–82.3] to 68.7 [59.8–74.7] mL/min per 1.73 m2, p  0.001) between baseline and 5 weeks. 
These changes were not considered clinically signiﬁ  cant. By 12 weeks these values had returned 
almost to baseline (Cr 95.5 [88.0–103.25] µmol/L, GFR 71.8 [65.3–77.4] mL/min). No patient 
had a serum creatinine rise 30%.
Conclusion: Most of patients with IC and a normal serum creatinine can be safely commenced 
on ramipril provided they are screened, titrated and monitored as described above. Studies in 
patients with borderline renal impairment (serum creatinine up to 30% above baseline) are 
on-going.
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Introduction
Best medical therapy (BMT) is the mainstay of treatment for patients with peripheral 
arterial disease (PAD) with endovascular or surgical intervention reserved for those 
who remain unacceptably symptomatic or have life and/or limb-threatening complica-
tions (Burns et al 2003).
In addition to smoking cessation therapies, hypertension and diabetic control, and 
antiplatelet and lipid lowering medication, the publication of the Heart Outcomes Pre-
vention Evaluation (HOPE) study has provided level 1 evidence to support the use of 
ramipril for secondary cardiac prevention in patients with PAD (The Heart Outcomes 
Prevention Evaluation Study Investigators 2000).
The HOPE study recruited patients with a history of cardiovascular disease (includ-
ing a cohort of 4051 (44%) patients with PAD) or a history of diabetes plus at least 
one other risk factor and randomized them to receive ramipril (titrated up to 10 mg) 
or placebo. At a mean follow-up of 4.5 years, ramipril signiﬁ  cantly reduced the com-
posite end-point (myocardial infarction, stroke, or death from cardiovascular causes) 
by 25%. This reduction in risk was at least as large as that observed for treatment with 
aspirin and lipid-lowering agents (Heart Protection Study Collaborative Group 2002; Vascular Health and Risk Management 2008:4(2) 472
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Peripheral Arterial Diseases Antiplatelet Consensus Group 
2003) and was independent of entry blood pressure.
Although the HOPE study indicated that the beneﬁ  ts of 
ACE inhibition in patients with PAD outweigh the risks, 
vascular surgeons remain wary of the small risk of precipi-
tating acute renal failure in patients with hemodynamically 
signiﬁ  cant renal artery stenosis (RAS) (Pillay et al 2002). The 
aim of this study was to evaluate in detail for the ﬁ  rst time, 
the effect of ramipril titration on renal function in a cohort of 
surgical PAD patients presenting with intermittent claudica-
tion, in the expectation that if safety could be demonstrated 
then this would change vascular surgeons’ practice.
Patients and methods
Local ethical approval was obtained and written informed 
consent was obtained from all patients. Patients, over the 
age of 55 years, attending the vascular surgical outpatient 
department of a large teaching hospital with a diagnosis 
intermittent claudication (IC) based on structured history 
(Leng and Fowkes 1992) and ankle brachial pressure index 
(ABPI) entered the study. Patients were excluded if they were 
currently receiving an ACE inhibitor or angiotensin receptor 
blocker, had abnormal baseline renal function (serum creati-
nine 120 µmol/L males, 110 µmol/L females), a history 
of severe renal artery stenosis (RAS), or were unwilling to 
participate. Patients who fulﬁ  lled the entry criteria were 
commenced on ramipril (Tritace® titration pack, Aventis 
Pharma UK), starting at 2.5 mg for 1 week, increased to 5 mg 
for 3 weeks and then further increased to the maintenance 
dose of 10 mg. Renal function was monitored by means 
of a blood sample collected after 1, 5, and 12 weeks and 
glomerular ﬁ  ltration rate (adjusted to a body surface area of 
1.73 m2) was estimated by means of the Modiﬁ  cation of Diet 
in Renal Disease (MDRD) Equation 7 (Levey et al 1999). 
The MDRD equation 7 requires serum creatinine, urea, and 
albumin values and it factors for the patient’s age, sex, and 
race. It has largely superseded the Cockcroft-Gault equation, 
as it has improved accuracy and does not require knowledge 
of the patient’s weight (Nation Kidney Foundation 2007). 
Ramipril was to be discontinued if the patient’s serum 
creatinine rose greater than 30% from their baseline value 
or if serum potassium rose 5.9 mmol/L, in line with our 
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Figure 1 Boxplots of change in serum creatinine in response to initiation of ramipril. Patients are commenced on ramipril 2.5 mg for 1 week, increased to 5 mg for 3 weeks, 
and then maintained on 10 mg. Compared with baseline, 1 week p = 0.015, 5 weeks p  0.001, 12 weeks p = 0.003, Wilcoxon signed ranks).Vascular Health and Risk Management 2008:4(2) 473
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recently published treatment algorithm (Hobbs et al 2004). 
Ramipril was also discontinued if the subject encountered 
unacceptable side effects.
Statistical analysis was performed using the SPSS 11.0 
for windows statistical package (SPSS Inc, Chicago, Ill). The 
Wilcoxon signed ranks test was used to analyze changes in 
creatinine and glomerular ﬁ  ltration rate (GFR) over time.
Results
One hundred and thirty-two consecutive patients (median 
age [interquartile range, IQR], 71 [62.25–78] years; 89 male) 
with IC were screened for study entry. Of these, 78 (59%) 
were excluded from the study for the following reasons. 38 
(29%) patients were already receiving an ACE inhibitor, 11 
(8%) were receiving an angiotensin receptor blocker, and 1 
patient was receiving both an ACE inhibitor and an angiotensin 
receptor blocker. 20 (15%) patients had biochemical evidence 
of renal impairment (median serum creatinine [IQR] 129 
[124–139] µmol/L). Of the remainder, 1 patient had a history 
of RAS and 7 (5%) patients were unwilling to participate.
Fifty-four (41%) patients (Table 1) fulﬁ  lled the entry 
criteria and were commenced on ramipril. ACE inhibition 
was discontinued during titration (within 5 weeks of start) 
due to adverse events in 3 patients (1 had exacerbation of 
angina and 2 reported dizzy episodes) and lack of compli-
ance with monitoring blood tests in 2. A further 5 patients 
were discontinued after titration to 10 mg, but before 12 
weeks. Three of these patients had adverse events (one each 
of cough, headaches, and arthralgia) and 2 failed to comply 
with monitoring blood tests. All of the four patients who were 
non-compliant with follow-up were contacted by telephone 
and none reported adverse events.
During titration to 10 mg ramipril, a small but statisti-
cally signiﬁ  cant rise in serum creatinine (median [IQR] cre-
atinine 94 [85.8–103.3] µmol/L to 98 [88.0–106.5] µmol/L, 
p  0.001) and fall in GFR (median [IQR] GFR 71.5 
[64.6–82.3] mL/min per 1.73 m2 to 68.7 [59.8–74.7] mL/
min per 1.73 m2, p  0.001) was observed. No patient had 
a serum creatinine rise greater than 30% from their baseline 
value and no patient had a serum potassium rise greater 
than 5.9 mmol/L. By 12 weeks renal function had almost 
returned to baseline levels (median creatinine [IQR] 96.5 
[88.3–103.8] µmol/L, p = 0.003 and median GFR [IQR] 69.8 
[65.0–76.9] mL/min per 1.73 m2, p = 0.015).
Discussion
This study demonstrates that using our treatment algorithm 
(Hobbs et al 2004), most patients presenting to vascular 
surgeons with a conﬁ  rmed diagnosis of IC and normal 
renal function can be titrated up to the evidence-based 
dose (10 mg) of ramipril with no deleterious effect to renal 
function. These novel data also suggest that the perceived 
risk of RAS in such patients exceeds the actual risk and 
in the presence of a normal baseline creatinine no further 
assessment of renal function or imaging of the renal arter-
ies is required prior to commencing ramipril. Although 
we have demonstrated short-term safety, it is important to 
remain vigilant as intercurrent illness and dehydration may 
precipitate impaired renal function in subjects receiving 
ACE inhibitors.
Level 1 evidence exists to support the use of ramipril 
for secondary cardiac prevention in patients with PAD 
manifest by: previous limb bypass surgery or percutaneous 
angioplasty; previous limb or foot amputation; history of 
intermittent claudication with ankle; arm blood pressure 0.8 
in at least one side; or a signiﬁ  cant stenosis (50%) docu-
mented by angiography (The Heart Outcomes Prevention 
Evaluation Study Investigators 1996). The recently published 
Inter-Society Consensus for the management of Peripheral 
Vascular Disease (TASC II) guidelines recommend that 
ACE inhibitors should be considered as ﬁ  rst line antihyper-
tensive treatment to reduce the risk of cardiovascular events 
(Inter-Society Consensus for the Management of Peripheral 
Arterial Disease 2007).
Despite this evidence, a large number of patients with 
PAD remain untreated. Part of the reason for this is that 
vascular surgeons remain cautious about commencing ACE 
Table 1 Demographic details of patients commenced on ramipril
Variable  
Number of subjects  54
Median age [IQR]  67.5 [59–76]
Sex (M:F ratio)  3.5:1
Ischemic heart disease 
Myocardial infarction/angina  8
Coronary artery bypass graft  1
Cerebrovascular disease 
Cerebrovascular accident  1
Transient ischemic attack  0
Diabetes mellitus  8
Hypertension 27
Medication
Antiplatelet agent  54
Statin   53
Antihypertensive 25
Insulin 2
Oral hypoglycemic  1
Mean ABPI (range)  0.72 (0.40–0.85)
Abbreviations: ABPI, ankle brachial pressure index; IQR, interquartile range.Vascular Health and Risk Management 2008:4(2) 474
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inhibitors in a patient population that has a high perceived 
risk of RAS. Although the incidence of RAS in patients 
with PAD is not well established, it has been reported to be 
between 20% and 50% in angiographic series, with 12% to 
24% of subjects having bilateral RAS (Choudhri et al 1990; 
Salmon and Brown 1990; Missouris et al 1994; Iglesias 
et al 2000). In practice, however, the incidence of RAS in 
our less selected group of patients with PAD is likely to 
be lower than this, since most patients with PAD do not 
have disease severe enough to warrant angiography and are 
likely to have correspondingly less advanced atheromatous 
renovascular disease.
In this study we have demonstrated a clinically insigniﬁ  -
cant, but statistically signiﬁ  cant, rise in serum creatinine and 
fall in GFR in response to titrating ramipril up to 10 mg over a 
5-week period. However, these levels return virtually to base-
line by 12 weeks and no patient had a serum creatinine rise of 
greater than 30% or developed hyperkalemia. Interestingly, in 
patients with pre-existing chronic renal insufﬁ  ciency, an early 
rise in serum creatinine of up to 30% with ACE inhibition is 
associated with long-term renal protection (Bakris and Weir 
2000). The mechanism is unknown, but it is thought that 
“remnant” or surviving nephrons may be subject to deleterious 
hyperﬁ  ltration. ACE inhibition, by causing vasodilatation of 
the efferent arteriole, may reduce this potentially deleterious 
hyperﬁ  ltration. The early fall in GFR may, therefore, herald 
a longer-term protective effect.
It is of note that 30% of patients screened for entry into this 
study were already receiving ACE inhibitors, predominantly 
for the treatment of hypertension or as secondary prevention 
following myocardial infarction. A further 11 patients were 
receiving an angiotensin receptor blocker for treatment of 
their hypertension. It is not yet known whether angiotensin 
receptor blockers confer the cardio protective beneﬁ  ts for 
this patient group that are evident with ramipril.
Ramipril is currently available generically at a cost of 
£14.24 for a 28-tablet pack (10 mg). This compares very 
favorably with other drugs used for cardiovascular risk 
reduction (eg, simvastatin 40 mg – £29.69 for a 28-tablet 
pack). Furthermore, several economic studies assessing the 
beneﬁ  ts of ramipril based on data from the HOPE study 
have all concluded that ramipril is highly cost effective 
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Figure 2 Boxplots of change in glomerular ﬁ  ltration rate in response to initiation of ramipril. Patients are commenced on ramipril 2.5 mg for 1 week, increased to 5 mg for 
3 weeks, and then maintained on 10 mg. Compared with baseline, 1 week p = 0.009, 5 weeks p  0.001, 12 weeks p = 0.015, Wilcoxon signed ranks).Vascular Health and Risk Management 2008:4(2) 475
ACE inhibitors and intermittent claudication
in the treatment of patients at high risk of cardiovascular 
events and that its use is likely to represent an efﬁ  cient use 
of resources (Bjorholt et al 2002; Lamy et al 2003; Smith 
et al 2003).
Although the current results show that most claudicants 
presenting to a vascular surgeon can safely be commenced 
on ACE inhibitors, the results may not be applicable to all 
subjects with IC. Firstly, 15% of patients had abnormal 
renal function at baseline and were therefore excluded from 
this present study. The median serum creatinine for these 
patients, however, was only moderately elevated (129 [IQR, 
124–139] µmol/L) and as such most could probably be safely 
commenced on ramipril, although this will need to be con-
ﬁ  rmed in a future study. Secondly, 11% of patients commenced 
on ramipril had to discontinue the drug due to the development 
of recognized side effects. Half of these side effects occurred 
while on the higher doses of the drug and potentially, therefore, 
these patients could have been maintained on a lower dose of 
ramipril. Lastly, a small proportion of patients were excluded 
as they were unwilling to commence a new tablet or unable 
to attend for surveillance blood tests. It may not be possible 
to extrapolate these results to subjects with more severe forms 
of PAD (eg, critical limb ischemia).
In conclusion, therefore, this study has demonstrated 
for the ﬁ  rst time that most patients presenting to vascular 
surgeons with IC can be safely commenced on ramipril 
provided the cautions and algorithm described above are 
adhered to. It is hoped that these novel data will change 
surgeons’ practice so that greater numbers of PAD patients 
will enjoy the very considerable beneﬁ  ts of this evidence-
based therapy.
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